New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
06:09 EDTTTHI, LLYTransition Therapeutics begins Phase 2 study of diabetes candidate TT-401
Transition Therapeutics (TTHI) dosed the first patient in a Phase 2 clinical study of TT-401, a drug candidate for the treatment of type 2 diabetes. The study is expected to enroll up to 375 type 2 diabetes subjects and will be performed by Transition's development partner, Eli Lilly (LLY). The objectives of the study will be to evaluate the safety and effectiveness of TT-401 compared to once-weekly exenatide extended release and placebo.
News For TTHI;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
06:34 EDTLLYEli Lilly CEO states company is not for sale, Financial Times says
Subscribe for More Information
February 23, 2015
08:31 EDTLLYEli Lilly announces delay in submission of basal insulin peglispro beyond Q1
Subscribe for More Information
07:06 EDTLLYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
February 19, 2015
08:04 EDTLLYEli Lilly extends Evacetrapib Phase 3 trial by six months
Subscribe for More Information
February 13, 2015
08:19 EDTLLYAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use